In a report released today, Richard Law CFA from Goldman Sachs initiated coverage with a Hold rating on Crinetics Pharmaceuticals and a price target of $36.00. The company’s shares opened today at $32.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Law CFA covers the Healthcare sector, focusing on stocks such as Nuvalent, Rocket Pharmaceuticals, and Crinetics Pharmaceuticals. According to TipRanks, Law CFA has an average return of 0.6% and a 41.03% success rate on recommended stocks.
Currently, the analyst consensus on Crinetics Pharmaceuticals is a Strong Buy with an average price target of $72.22.
Based on Crinetics Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $361 thousand and a GAAP net loss of $96.77 million. In comparison, last year the company earned a revenue of $640 thousand and had a GAAP net loss of $66.93 million
Read More on CRNX:
- Crinetics initiated with a Neutral at Goldman Sachs
- Crinetics Pharmaceuticals: Strategic Advancements and Promising Pipeline Drive Buy Rating
- Crinetics Pharmaceuticals Presents at ENDO 2025 Meeting
- 3 Best Stocks to Buy Now, 6/30/2025, According to Top Analysts
- Crinetics Pharmaceuticals: Promising Pipeline and Strategic Focus Drive Buy Rating